Improvement of Systemic Human Immunodeficiency Virus--Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy | Zendy

E. Vaccher | Zendy; Michele Spina | Zendy; R. Talamini | Zendy; Martina Zanetti | Zendy; Gisella Gennaro | Zendy; Guglielmo Nasti | Zendy; Marcello Tavio | Zendy; Daniele Bernardi | Zendy; Claudia Simonelli | Zendy; Umberto Tirelli | Zendy

Open Access

Improvement of Systemic Human Immunodeficiency Virus--Related Non-Hodgkin Lymphoma Outcome in the Era of Highly Active Antiretroviral Therapy

Author(s) -

E. Vaccher,

Michele Spina,

R. Talamini,

Martina Zanetti,

Gisella Gennaro,

Guglielmo Nasti,

Marcello Tavio,

Daniele Bernardi,

Claudia Simonelli,

Umberto Tirelli

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/379517

Subject(s) - medicine , hazard ratio , lymphoma , confidence interval , proportional hazards model , antiretroviral therapy , non hodgkin's lymphoma , sida , retrospective cohort study , multivariate analysis , systemic therapy , human immunodeficiency virus (hiv) , oncology , viral disease , viral load , immunology , cancer , breast cancer

To assess the impact of highly active antiretroviral therapy (HAART) on the outcome of systemic human immunodeficiency virus-related non-Hodgkin lymphoma (HIV-NHL), we retrospectively analyzed 235 patients in whom HIV-NHL was diagnosed from April 1988 through December 1999. A multivariate Cox proportional hazards model was used to estimate prognostic factors for overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS). Complete remission occurred in 49% of patients, and the 3-year rates of OS, PFS, and DFS were 19%, 49%, and 73%, respectively. The greatest risk for shortened OS, PFS, and DFS was associated with no HAART use (compared with long-term HAART use); hazard ratios were 17.42 (95% confidence interval [CI], 17.42-40.25), 9.11 (95% CI, 3.71-22.32), and 8.54 (95% CI, 1.19-61.11), respectively. Our study suggests that the long-term use of HAART may favorably change the outcome for patients with systemic HIV-NHL.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research